Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2014; 6(6): 145-155
Published online Jun 15, 2014. doi: 10.4251/wjgo.v6.i6.145
Published online Jun 15, 2014. doi: 10.4251/wjgo.v6.i6.145
Operable gastro-oesophageal junctional adenocarcinoma: Where to next?
Elizabeth C Smyth, David Cunningham, Department of Gastrointestinal Oncology, Royal Marsden Hospital, Sutton SM2 5PT, United Kingdom
Author contributions: Smyth EC and Cunningham D both contributed to the paper.
Supported by NIHR RM/ICR Biomedical Research Centre
Correspondence to: Dr. Elizabeth Smyth, Department of Gastrointestinal Oncology, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, United Kingdom. elizabeth.smyth@rmh.nhs.uk
Telephone: +44-208-6426011
Received: January 8, 2014
Revised: April 2, 2014
Accepted: April 11, 2014
Published online: June 15, 2014
Processing time: 163 Days and 13 Hours
Revised: April 2, 2014
Accepted: April 11, 2014
Published online: June 15, 2014
Processing time: 163 Days and 13 Hours
Core Tip
Core tip: Cancer of the gastro-oesophageal junction is an increasingly common phenomenon. For patients with operable junctional cancer, the only curative treatment option is surgery, however the optimal peri-operative treatment is controversial. We review the evidence supporting the use of chemotherapy and chemoradiotherapy in the pre- and postoperative settings for these patients, and go on to highlight how current research into the molecular mechanisms underpinning gastro-oesophageal cancer may lead to future effective treatment options.